Ohio State Navbar

News


Register For The 2014 ASH Review


January 09, 2014

Kristie Blum, MD, an associate professor in the Division of Hematology at Ohio State and a member of the Molecular Biology and Cancer Genetics Program at the OSUCCC – James, will be the keynote speaker at Ohio State’s 2014 ASH Review, which will unfold from 7:30 a.m.-4 p.m. on Friday, Jan. 31, in Room 115 of the Biomedical Research Tower. Blum is an expert in novel therapies for lymphoma, particularly the targeted agent ibrutinib. The annual conference will provide a comprehensive review of advances in the biology, etiology, diagnosis, therapy and evidence-based management of blood cancers as presented at the 2013 American Society of Hematology (ASH) annual meeting held Dec. 7-10 in New Orleans. The ASH review is intended for primary care physicians, hematologists and oncologists, researchers, nurses and other healthcare professionals involved in hematology. There is no fee to attend, but registration is required at go.osu.edu/ASHREVIEW. Questions? Contact Katie Jones at katie.jones@osumc.edu of 366-5183. The rest of the story



AML Score That Combines Genetic and Epigenetic Changes May Help Guide Therapy


January 09, 2014

Currently, doctors use chromosome markers and gene mutations to determine the best treatment for a patient with acute myeloid leukemia (AML). But a new study suggests that a score based on seven mutated genes and the epigenetic changes that the researchers discovered were present might help guide treatment by identifying novel subsets of patients. The findings, published in the Journal of Clinical Oncology, come from a study led by researchers at the OSUCCC – James. Clara D. Bloomfield, MD, a Distinguished University Professor who also serves as OSU cancer scholar and senior adviser for the OSUCCC – James, was principal investigator for the study, and Guido Marcucci, MD, a professor in the Division of Hematology at Ohio State who also serves as associate director for translational research at the OSUCCC – James, was first author. The rest of the story



Study Confirms Target of Potent Chronic Leukemia Drug


January 09, 2014

A study led by researchers at the OSUCCC – James helps confirm that a molecule targeted by the experimental drug ibrutinib is critical for the development of chronic lymphocytic leukemia, the most common form of adult leukemia. Amy Johnson, PhD, associate professor in the Division of Hematology and an OSUCCC – James researcher, was principal investigator for the study, which was published in the journal Blood. The rest of the story



Celebrate MMORE GALA, February 8, 2014


November 13, 2013

This wonderful evening includes fabulous appetizers and dinner, inspirational presentations, unique items in silent and live auctions, music and dancing. The rest of the story



Ohio State Saddened By Passing of Dr. Bertha Bouroncle


September 05, 2013

Ohio State Saddened By Passing of Dr. Bertha Bouroncle. Bertha A. Bouroncle, MD, a professor emerita of Internal Medicine at Ohio State who was the first to identify hairy cell leukemia and later helped develop an effective therapy for it, died Aug. 16 surrounded by family and friends at the Ross Heart Hospital. The rest of the story



Pierluigi Porcu, MD, elected to a three-year term as president of the United States Cutaneous Lymphoma Consortium (USCLC)


September 05, 2013

Pierluigi Porcu, MD, elected to a three-year term as President of the United States Cutaneous Lymphoma Consortium (USCLC) The rest of the story



OSUCCC - James Named One of the Top 20 Best Cancer Hospitals


July 16, 2013

OSUCCC - James Named One of the Top 20 Best Cancer Hospitals The rest of the story



Drug Shows Potential as Safe and Effective for Chronic Leukemia, Mantle Cell Lymphoma


June 20, 2013

Drug shows surprising efficacy as treatment for chronic leukemia, mantle cell lymphoma The rest of the story



Congratulations to Dr. Leslie Andritsos and Dr. Don Benson


May 23, 2013

Excellence in Teaching Awards 2013- from Student Programs The rest of the story



Dr. Robert Baiocchi Merging Innovations with Commercialization


April 23, 2013

Dr. Robert Baiocchi Merging Innovations with Commercialization The rest of the story



Previous     Next